Interaction Checker

Naltrexone interactions

Naltrexone (Vivitrol, Revia), an opioid antagonist has 49 documented interactions across the FDA labels and fact sheets we index: 25 major, 1 moderate, 21 minor, and 2 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Major interactions (25)

  • Bictegravir, emtricitabine, and tenofovir alafenamideantiretroviralMajor

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Bictegravir, emtricitabine, and tenofovir alafenamide label, Drug interactions)

  • BuprenorphineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Buprenorphine and naloxoneopioidMajor

    Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • ButorphanolopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • CodeineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • EluxadolineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • FentanylopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Hydrocodone and acetaminophenopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • HydromorphoneopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • LevorphanolopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • MeperidineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • MethadoneopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Methylnaltrexoneopioid antagonistMajor

    • Other Opioid Antagonists : Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use. (Methylnaltrexone label, Drug interactions)

  • MorphineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • NalbuphineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Naldemedineopioid antagonistMajor

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Naldemedine label, Drug interactions)

  • Naloxoneopioid antagonistMajor

    Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Nirmatrelvir and ritonavirantiviralMajor

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (Nirmatrelvir and ritonavir label, Contraindications)

  • OliceridineopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • OxycodoneopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Oxycodone and acetaminophenopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • OxymorphoneopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • Pentazocine and naloxoneopioidMajor

    Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • TapentadolopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

  • TramadolopioidMajor

    Naltrexone for extended-release injectable suspension is contraindicated in: Patients receiving opioid analgesics [see Warnings and Precautions ( 5.3 ) ] . (Naltrexone label, Contraindications)

Moderate interactions (1)

  • Lofexidinealpha-adrenergic agonistModerate

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (Lofexidine label, Drug interactions)

Minor mentions (21)

  • AlcoholAlcoholMinor

    Precipitation of Opioid Withdrawal : Opioid-dependent and opioid-using patients, including those being treated for alcohol dependence, should be opioid-free before starting naltrexone for extended-release injectable suspension treatment, and should notify healthcare providers of any recent opioid use. (Naltrexone label, Warnings and precautions)

  • BeclomethasonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • BetamethasonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • BudesonidecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • ClobetasolcorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • DesonidecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • DexamethasonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • FludrocortisonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • FluocinonidecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • FluticasonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • HalobetasolcorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • HydrocortisonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • KetamineCNS depressantMinor

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrexone label, Warnings and precautions)

  • MethylprednisolonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • MometasonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • PrednisolonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • PrednisonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

  • PropofolCNS depressantMinor

    The opioid therapy must be provided by individuals specifically trained in the use of anesthetic drugs and the management of the respiratory effects of potent opioids, specifically the establishment and maintenance of a patent airway and assisted ventilation. (Naltrexone label, Warnings and precautions)

  • TriamcinolonecorticosteroidMinor

    Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (Naltrexone label, Warnings and precautions)

No significant interaction reported (2)

  • AcamprosateNo interaction

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (Acamprosate label, Drug interactions)

  • Emtricitabine and tenofovirantiretroviralNo interaction

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (Emtricitabine and tenofovir label, Drug interactions)

Check Naltrexone against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.